BACKGROUND: Histone deacetylase inhibitors (HDACI) are members of a family of epigenetic modifying agents with broad anti-inflammatory properties.
A cute lung injury (ALI) and acute respiratory distress syndrome (ARDS) represent a spectrum of an inflammatory pulmonary disease, manifesting clinically with severe hypoxia and dyspnea. 1 The syndrome, which was first described in 1967, is characterized by systemic release of proinflammatory mediators and diffuse infiltration of the pulmonary parenchyma with inflammatory cells. 2 Neutrophil recruitment to the lungs can lead to widespread pulmonary vascular endothelial and alveolar epithelial cell damage and death, intrapulmonary hemorrhage, pulmonary edema due to disruption of the blood-alveolar barrier, and severely impaired gas exchange leading to respiratory failure. 3 The syndrome is usually the result of highly inflammatory disease states that may be affecting the lungs directly (pneumonia, aspiration, pulmonary contusion, near-drowning, toxic inhalation) or indirectly (sepsis, severe multiorgan trauma, multiple transfusions, drug overdose, pancreatitis). 3 More than 200,000 cases of ARDS -the definition of which was recently expanded to encompass ALI 2 -are diagnosed annually in the United
States alone, that are associated with 3.6 million hospital days. 4 Although mortality from ARDS appears to be improving at least in the setting of clinical trials, it remains very high, averaging above 45%, and even exceeding 60% in the most severe cases. 5 This makes ARDS even more lethal than myocardial infarction and embolic stroke. 6, 7 Moreover, long-term disability in ARDS survivors can be significant: A longitudinal study that followed up ARDS survivors over 5 years demonstrated major physical and psychological sequelae, including significant exercise limitation, poor quality of life, and increased costs associated with healthcare utilization. 8 Despite advances in critical care and mechanical ventilation technology over the last few decades, treatment for ARDS remains largely supportive, [9] [10] [11] whereas targeted therapies have failed to improve clinically relevant outcomes, including survival in human clinical trials. [12] [13] [14] The above emphasize the need to identify novel therapeutic approaches, with the aim to mitigate excessive lung inflammation and improve outcomes of this host-response disease.
ARDS represents a clinical syndrome resulting from an exaggerated immune response to noxious stimuli that is triggered from overexpression of a multitude of chemokines and activation of recruited and resident inflammatory cells. [15] [16] [17] [18] [19] [20] In that regard, epigenetic modification of the harmful inflammatory pathways that become activated early in the disease course may present a unique opportunity for development of specific, targeted therapies, and may hold promise at preventing ARDS from developing and improving clinically relevant outcomes in the management of patients with or at risk for ARDS. Preliminary studies using murine models of ARDS have mitigated the systemic and pulmonary inflammatory profile and improved survival in animals pretreated with histone deacetylase inhibitors (HDACI). 21, 22 However, the studies published to date have not used clinically relevant models, in which animals receive treatment after the original inflammatory insult is applied, and the effect of this new anti-inflammatory therapy has not been adequately assessed on bacterial dissemination, given most cases of ARDS arise from severe infections. 4 The aim of the current project is to determine whether valproic acid (VPA), one of the most widely used HDACI, ameliorates the inflammatory response in a murine model of Escherichia coli pneumonia-induced ALI (one of the most common models of the disease 23 ), if administered shortly after the stimulus, and what its effect on pulmonary bacterial load is, once the immune response is lessened.
MATERIALS AND METHODS

Mice
Male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were allowed to acclimate for a minimum of 3 days and maintained under specific pathogen-free conditions in a fullbarrier facility until experiments, at 6 weeks to 8 weeks of age. All mice were allowed food and water ad libitum, and all procedures were conducted after approval by Boston University's Institutional Animal Care and Use Committee, and in accordance with guidelines for ethical animal treatment.
Escherichia Coli
Escherichia coli (serotyp. 06:K3:H1, strain 19138; American Type Culture Collection, Manassas, VA) was cultured to the desired concentration in Luria broth. E. coli was quantified by optical density and verified by serial dilutions on Luria broth plates.
Endotracheal Instillations and ALI
After anesthesia with inhaled isofluorane, mice underwent direct endotracheal instillation using the tongue pull technique. The animals were suspended by their front incisors on an angled surgery board, and their tongue was retracted outward with DeBakey forceps to allow access to their larynx. Fifty microliters of sterile normal saline (n = 6) or 3 Â 10 6 of E. coli in the same amount of saline (n = 24, per previously published listerature 21 ) was instilled endotracheally by pipette. Mice were returned to their home cage once consciousness was regained. Of the 24 mice that were challenged with E. coli, half were randomly selected and administered 250 mg/kg of VPA (Selleck Chemicals, Boston, MA) and the other half sterile normal saline intraperitoneally 30 minutes postendotracheal instillation (Fig. 1) .
Blood was collected 3 and 6 hours after E. coli challenge via facial vein or cardiac puncture, respectively. Immediately after euthanasia at 6 hours, the animals underwent thoracotomy and had their left hilum ligated, whereas their trachea was surgically exposed, and a tracheostomy with a 22G angiocath was performed. This time point was selected consistent with previous published methodology. 21, 23, 24 Bronchoalveolar lavage (BAL) of the right lung was performed with Hanks Buffered Salt Solution Ethylene Diamine Triacetic Acid in a stepwise fashion until 1 mL of BAL fluid (BALF) was obtained. Cell count and differential were obtained in the BALF (Cytospin: ThermoScientific, Waltham, MA).
Histology and Confirmation of ALI
The left lung was fixed in 4% formalin, embedded in paraffin, sectioned, and mounted on microscopy slides. The nonlavaged lung was selected for histologic assessment to eliminate the risk of identifying alveolar wall destruction or similar pathology due to possible overdistention during lavage. The samples were then dehydrated, processed with xylene, and stained with hematoxylin and eosin. Images were examined and captured with an Olympus Upright microscope with X software version X (Olympus Corporation, Tokyo, Japan).
In a pilot experiment to be published elsewhere, using the same method and dose for E. coli endotracheal instillations and lung staining, but without BAL, we confirmed in animals sacrificed at the same time point, that diffuse neutrophil infiltration, alveolar damage and hemorrhage, and alveolar wall thickening with hyaline deposition and pulmonary edema were present in all 5 pulmonary lobes, as well as ratios of Pao2/ FiO2 < 300 were present, thus ensuring satisfactory creation of a murine ARDS model.
Myeloperoxidase Activity Assay
Assessment of myeloperoxidase (MPO) activity was performed as previously described, 25 as a measure of neutrophil activation in the pulmonary parenchyma. The absorbance was read at 450 nm, and data were expressed as change in optical density (ΔOD, the difference between the average absorbance of the three substrate wells and the three background wells for the same sample). 
Cytokine Expression
The proinflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), CXCL1 (also known as KC), CXCL2 (also known as macrophage inflammatory protein-2, [MIP-2]), and angiopoietin-2 levels were determined in samples by enzyme-linked immunosorbent assay per the manufacturers' instructions (TNF-α and IL-6; eBioscience, San Diego, CA; MIP2, KC: R&D Systems, Minneapolis, MN; Angiopoietin 2; Abcam, Cambridge, MA). These cytokines were selected for measurement, because they are implicated in the pathophysiology of ARDS in both human and animals as proinflammatory (TNF-α, IL-6), or neutrophil-attracting chemokines (KC, MIP-2), [15] [16] [17] [18] [19] or they have been recently identified as potential early biomarkers for the clinical syndrome (angiopoietin-2). 26 TNF-α, IL-6, KC, and MIP-2 were measured in the BALF at the time of sacrifice (6 hours), whereas IL-6 and angiopoietin-2 in plasma at 3 and 6 hours.
Transalveolar-Capillary Membrane Protein Transit
Albumin and immunoglobulin M (IgM) levels were assessed in the BALF by enzyme-linked immunosorbent assay (Bethyl Laboratories, Montgomery, TX) to assess degree of transalveolar-capillary membrane protein transit, a marker of alveolar wall destruction and alveolar-capillary membrane permeability.
Bacterial Burden
Viable bacteria were quantified by colony counting, 17, 20 after serial dilutions of BALF were plated on blood agar, and colony-forming units/mL were enumerated after incubation at 37°C for 48 hours.
Statistics
Student's t test or one-way analysis of variance were performed to compare means between intervention groups as appropriate. Data are reported as means ± standard deviations as appropriate. Statistical significance was declared at a two-sided p value of ≤0.05. Statistical analyses were performed with Prism 6.0 (GraphPad Software, La Jolla, CA).
RESULTS
Histopathology, Neutrophil Recruitment, and Activation
Although lung sections from sham animals demonstrated normal pulmonary parenchymal architecture ( Fig. 2A) , sections obtained post mortem from the isolated left lung of the animals instilled with E. coli exhibited acute inflammatory histopathology consistent with ALI, numerous neutrophils were noted in the alveolar air spaces, in the perivascular connective tissue, and the air spaces and interstitium of the conducting airways. 17 Diffuse pulmonary edema was evident by fibrin deposition within the air spaces, and the expansion of the interstitial and lymphatic compartments. Focal hemorrhage with red cell extravasation into the pulmonary parenchyma suggestive of vascular endothelial disruption; alveolar wall thickening; and loss of parenchymal architectural integrity were also noted (Fig. 2B) . The animals treated with VPA demonstrated improved histopathology. Neutrophil recruitment -a hallmark of acute inflammation and ALI 27,28 -was significantly decreased, fewer neutrophils could be seen throughout the pulmonary parenchyma after VPA administration, and the expansion of the interstitial and lymphatic compartments suggestive of pulmonary edema was mitigated. Red cell extravasation was less pronounced, and architectural integrity was preserved to a greater extent (Fig. 2C) .
Cytology of the BALF on cytospin demonstrated a few resident macrophages in the sham animals (Fig. 2D) , with many more neutrophils having been recruited in the BALF of the E. coli-instilled mice. The number of the macrophages seen was similar to that of the sham animals; however, it is likely the time of sacrifice (6 hours) may have precluded more macrophages from emigrating into the lungs this early on (Fig. 2E) . The number of macrophages was also relatively stable in the VPA-treated mice, but the recruited neutrophils were significantly reduced (Fig. 2F) .
Numeric assessment of the macrophage and neutrophil counts in the BALF confirmed the above observation ( Fig. 3A and B), and so did neutrophil MPO assessment (Fig. 3C ).
Cytokine Expression
The proinflammatory cytokines TNF-α and IL-6 were measured in the plasma and in the BALF. Both cytokines were noted to be significantly elevated in the instilled animals' BALF compared with the shams, and both were diminished after VPA administration, suggesting an ameliorated inflammatory response secondary to the HDACI administration. Compared with the sham animals, the IL-6 levels measured in the bloodstream at both 3 hours and 6 hours were elevated (Fig. 4) . 21 TNF-α levels in plasma were below the level of detection. VPA led to a statistically significant reduction in both these cytokines at both time points. Although angiopoietin-2 has recently been identified as a promising biomarker in predicting development of ARDS in humans, 26 we were not able to replicate this finding in our experiments in mice, with its levels in sham animals not being different compared to animals with ALI and those that received VPA. BALF chemokines MIP-2 and KC were increased compared to shams in the E. coli-instilled animals; however, VPA appeared to affect only the former. These data suggest that histone acetylation helps limit the expression of proinflammatory cytokines and neutrophil migration during E. coli pneumonia early on.
Transalveolar-Capillary Membrane Protein Transit
An important result of lung infection and resulting inflammation is decompartmentalization, in which the normally tight alveolar epithelial barrier is compromised and large circulating molecules from the bloodstream may extravasate into the alveolar space and locally produced proinflammatory cytokines can spill over into the systemic circulation. 17, 29, 30 This pulmonary endothelial and capillary membrane injury from the local infection led to increased permeability between the sham and E. coli-instilled animals, and-as demonstrated earlier-the systemic IL-6 levels were elevated at both 3 hours and 6 hours after E. coli instillation compared with the E. colinaïve animals. Both measurements were decreased with VPA administration. Conversely, significantly larger IgM leakage into the BALF and a trend toward greater albumin transit was noted in the E. coli-challenged animals. Despite the ameliorated inflammatory response in the VPA-treated animals, there was a trend toward lower plasma extravasation into the alveolar air spaces; however, this did not reach statistical significance (Fig. 5) . The maintenance of the alveolar-capillary barrier in the VPA-treated mice is also suggested by the fewer extravasated red cells seen in the alveolar space of the sectioned pulmonary parenchyma (Fig. 1C) .
Pulmonary Bacterial Burden
Any bacterial infection in an immune competent host leads to an inflammatory response and activation of numerous bactericidal pathways, in an attempt to curb bacterial proliferation. As might have been expected from the mitigated inflammatory response and the impaired neutrophil migration into the lungs, the VPA-treated animals' bactericidal activity was compromised, and the E. coli bacterial burden was exaggerated in these mice (Fig. 6) .
DISCUSSION
Any bacterial infection in an immune competent host leads to an inflammatory response that includes neutrophil recruitment to the site of infection and activation of numerous bactericidal pathways, in an attempt to curb microbial proliferation. This response, in addition to bacterial killing, commonly leads to host tissue destruction, which when exaggerated, may in itself be more harmful than the original inflammatory stimulus. ALI/ARDS represents one such example, in which the diffuse pulmonary neutrophil recruitment and alveolar epithelial membrane disruption result in intraparenchymal hemorrhage, decompartmentalization, and severely impaired gas exchange. These changes may be recognized regardless of whether the primary inflammatory insult was infectious or not. Numerous antiinflammatory strategies have been tried in the past in an attempt to mitigate the clinical sequelae of ARDS with no clinical benefit in humans. 12, 13, 31 It appears that anti-inflammatory regimens have no effect in reversing the course of disease once neutrophil recruitment and pulmonary parenchymal destruction have peaked, events that typically occur early on, before the fullblown clinical syndrome reaches its zenith. This observation allowed the focus of management of ARDS to be shifted from treating patients with it, to establishing strategies that prevent it in patients with potent enough inflammatory stimuli. 32 Thankfully, recent work appears to have yielded satisfactory risk stratification tools toward identifying patients at risk for developing ARDS. [32] [33] [34] An approach tailored around administering early anti-inflammatory therapies in patients with severe pneumonia or aspiration, sepsis, extensive burns, multiorgan trauma, or any other source of a major systemic inflammatory response, could pave the way toward improving ARDS-related morbidity and mortality.
In our experiment, we demonstrate that a pharmacological agent known to be a histone deacetylation inhibitor attenuated expression of IL-6, TNF-α, and MIP-2 decreased neutrophil migration to the pulmonary parenchyma, and improved decompartmentalization, overall minimizing the infection-induced lung injury and improving the histopathologic changes consistent with ALI. As a result of the impaired proinflammatory cytokine production and neutrophil recruitment, bacterial proliferation became uncontrolled to a greater degree in the HDACI-treated mice. One of the key mechanisms by which bacterial infections trigger an inflammatory response in the host aimed at curbing the infection is through the toll-like receptor (TLR), myeloid differentiation factor 88 (MyD88), interleukin-1 receptor kinase (IRAK1) and NF-κB pathway: Pathogen-Associated Molecular Patterns interface with macrophage plasma membrane TLRs and signal through MyD88 and IRAK1 to stimulate nuclear translocation of NF-κB, subsequently turning on the transcription of proinflammatory cytokines. 35, 36 These κB-regulated proteins include KC, MIP-2, TNF-α, IL-6, and IL-1b and have been shown to play a pivotal role in the pathogenesis of lung injury. 19, [37] [38] [39] It is conceivable, therefore, that by timely curbing overexpression of these cytokines, histopathologic changes that lead to ALI may be minimized. 17 Although histone deacetylase inhibition has been used with success in animal models with a variety of septic insults, 40, 41 the mechanisms by which it diminishes expression of proinflammatory mediators remain largely speculative. Histone deacetylase inhibition can decrease MyD88 and IRAK1 protein expression, likely by enhancing their degradation due to heat shock protein 90 hyperacetylation, thereby preventing NF-κB nuclear translocation and cytokine expression in vivo. 42 This represents at least one possible mechanism by which the κB-regulated proteins become underexpressed with HDACI. The mechanism by which VPA diminishes cytokine expression now becomes an important focus for further study.
One downside of histone deacetylase inhibition in the presence of an acute pulmonary bacterial infection is that the downregulation of the microbicidal host immune response impairs local bacterial clearance in the lungs. Similar findings have been observed in numerous other related settings, including but not limited to the deficiency of NF-κB RelA, MyD88, or early response cytokines TNF and IL-1. 43 Due to the decreased neutrophil migration, an additional factor mitigating alveolar destruction may be the decreased MPO activity, a key lysosomal enzyme present in azurophilic granules released extracellularly during neutrophil degranulation. MPO not only is necessary for bacterial killing, it has also been increasingly implicated in the pathogenesis of ARDS 44, 45 by differentially affecting expression of claudins, molecules responsible for the maintenance of tight junctions between pneumocytes 46,47 and indirectly upregulating MIP-1 synthesis, 44 further perpetuating neutrophil emigration to the lungs and propagating lung injury. Unlike neutrophils, we did not identify a change in the macrophage count in the BAL, however, the samples were obtained somewhat early on, at 6 hours, limiting potential migration of extra-alveolar monocytes/macrophages that typically takes place later on. 48, 49 In future experiments, we plan on assessing the role of macrophages in the pathogenesis of ARDS in greater detail.
Despite the amount of attention angiopoietin-2 has recently received, not only as a proangiogenic factor but also as an important inflammatory mediator, 50 a surrogate marker for the degree of pulmonary endothelial inflammation, 51 and a predictor of development of multiorgan failure 52 and ARDS, 26 we were not able to identify an association between the severity of lung injury and its levels in our experiments. We found some levels of angiopoietin-2 to be constitutionally expressed in the sham animals, and its levels did not change significantly in the presence of infection and significant lung injury, suggesting that in mice, this molecule perhaps has nonhomologous function compared with its human counterpart, or its role in ARDS may not have been reflected in this particular disease model.
Attenuation of the lung injury in bacterial pneumonias, currently the most common cause of ALI/ARDS, may have Figure 6 . B, Bacterial burden was significantly increased in the VPA-treated mice. (** p < 0.01).
significant translational implications should it be considered for use in patients with early ARDS or at risk for it. Even though other anti-inflammatory therapies have been evaluated in human clinical trials with poor results in the past, 12, 13, 31 it is likely their delayed administration during the full-blown phase of the clinical syndrome precluded any significant clinical benefits. Contrasting these findings with our preliminary results that demonstrate an ameliorated syndrome, it is possible that a therapeutic window of time exists, and if potent anti-inflammatory therapies are administered early -shortly after the original inflammatory insult and before the full-blown syndrome of ALI/ ARDS develops, clinically relevant benefits may be anticipated.
There are numerous limitations to our model, including no assessment of pulmonary function, survival, and long-term outcomes, as well as the role of antibiotherapy, optimal dosing of VPA or other narrow-spectrum HDACI, or identification of specific molecular pathways that are implicated in the pathophysiology of the syndrome that may become more specific therapeutic targets in the future. However, we aim to tackle these research questions one at a time. 
